0001209191-23-056355.txt : 20231121 0001209191-23-056355.hdr.sgml : 20231121 20231121180022 ACCESSION NUMBER: 0001209191-23-056355 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231117 FILED AS OF DATE: 20231121 DATE AS OF CHANGE: 20231121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Teehan Brendan CENTRAL INDEX KEY: 0001891900 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 231429411 MAIL ADDRESS: STREET 1: C/O ACADIA PHARMACEUTICALS INC. STREET 2: 12830 EL CAMINO REAL, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-17 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001891900 Teehan Brendan C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 0 1 0 0 EVP, COO, Head of Commercial 0 Common Stock 2023-11-17 4 M 0 4956 A 30397 D Common Stock 2023-11-17 4 M 0 4956 A 35353 D Common Stock 2023-11-20 4 S 0 4960 22.64 D 30393 D Restricted Stock Units 2023-11-17 4 M 0 4956 0.00 D Common Stock 4956 19826 D Restricted Stock Units 2023-11-17 4 M 0 4956 0.00 D Common Stock 4956 19826 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Includes 707 and 378 shares of the Issuer's common stock acquired by the reporting person on May 15, 2023 and November 15, 2023, respectively, pursuant to an employee stock purchase program. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $22.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. /s/ Austin D. Kim, Attorney-in-Fact 2023-11-21